Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules. In VISTA, the regimen comprised four 6-week twice-weekly cycles, plus five 6-week onc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mateos, María-Victoria, Bringhen, Sara, Richardson, Paul G., Lahuerta, Juan Jose, Larocca, Alessandra, Oriol, Albert, Boccadoro, Mario, García-Sanz, Ramón, Di Raimondo, Francesco, Esseltine, Dixie-Lee, van de Velde, Helgi, Desai, Avinash, Londhe, Anil, San Miguel, Jesús F., Palumbo, Antonio
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2014
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4040917/
https://ncbi.nlm.nih.gov/pubmed/24763402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.099341
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars